Statement re. Suspension (2725G)

TIDMNGG

RNS Number : 2725G

NextGen Group PLC

27 June 2012

NextGen Group plc

("NextGen" or the "Company")

Statement re suspension of trading

NextGen Group Plc (AIM: NGG), the AIM listed company developing its own diagnostics product pipeline and providing diagnostic biomarker development services, announces that Klaus Rosenau, Chairman, is seriously ill following a heart attack. The Board's thoughts are very much with Klaus' family at this difficult time.

The Company is in the final stages of agreeing a fundraising with new investors to secure its ongoing working capital requirements, but Mr Rosenau's illness means that it is unclear when this may be consummated.

As a consequence, the Company has today requested that trading in the Company's ordinary shares on AIM should be suspended pending clarification of its financial position.

ENDS

For further details please contact:

Leif Hamoe

CFO

NextGen Group

Tel: +45 4033 4083

Barry McAleer PhD MBA

CEO

NextGen Sciences Inc and NextGen Sciences Dx Inc

Tel: +44 (0)7825 413 110

Jonathan Wright

Tel: + 44 (0)20 7107 8000

Seymour Pierce Limited

Notes to Editors:

NextGen Group Plc (AIM: NGG) is a developer of diagnostic markers and products through its US-based subsidiary, NextGen Sciences Dx Inc and is a provider of diagnostic biomarker development services for pharmaceutical and biotech companies globally through its second US-based subsidiary, NextGen Sciences Inc. Using advanced techniques, such as Multiple Reaction Monitoring (MRM) mass spectrometry analysis, the Company is developing a portfolio of robust assays for testing clinical samples for drug safety and efficacy, and the development of personalized treatment for patients.

NextGen Sciences Inc is a wholly owned, operational subsidiary of NextGen Group Plc and is headquartered in Ann Arbor, Michigan, USA. NextGen Sciences' range of services, which include biomarker discovery, assay development, validation and testing are employed by its customers as a key part of the biomarker-based drug and diagnostic development process.

NextGen Sciences Dx Inc is a wholly owned, operational subsidiary of NextGen Group Plc and is headquartered in Boston, Massachusetts, USA. NextGen Sciences Dx utilises the expertise of NextGen Sciences Inc to discover biomarkers and develop assays for point-of-care diagnostics, to assist in patient treatment, for selection of patients for clinical trials and to aid decision-making on efficacy determination for therapeutic development.

This information is provided by RNS

The company news service from the London Stock Exchange

END

SRSUBAURUAANUAR

Nextgen (LSE:NGG)
過去株価チャート
から 5 2024 まで 6 2024